Chronic hepatitis C treatment patterns in African American patients: An update

American Journal of Gastroenterology

Volumn 100, Issue 3, 2005, Pages 716-722

  Daniel, Samuel ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NORTH GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AFRICAN AMERICAN; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG TOLERABILITY; ETHNIC GROUP; FEMALE; GENETIC DIFFERENCE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; INFECTIOUS COMPLICATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW;

AFRICAN AMERICANS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 16844383683     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.41321.x     Document Type: Review

References (58)

1. Fleckenstein J. Chronic hepatitis C in African Americans and other minority groups. Curr Gastroenterol Rep 2004;6:66-70.
2. World Health Organization. Hepatitis C-Global prevalence (update). Wkly Epidemiol Rec 2000;75:18-9.
3. Kim M. The burden of hepatitis C in the United States. Hepatology 2002;36:S30-4.
4. McHutchison JG. Understanding hepatitis C. Am J Manag Care 2004;10:S21-9.
5. Szabo E, Lotz G, Paska C, et al. Viral hepatitis: New data on hepatitis C infection. Pathol Oncol Res 2003;9:215-21.
6. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
7. Simmonds P. Viral heterogeneity of the hepatitis C virus. J Hepatol 1999;31(Suppl 1):54-60.
8. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
9. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
10. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
11. Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: Its natural history and histological progression. Am J Gastroenterol 2002;97:700-6.
12. Reddy KR, Hoofnagle JH, Tong MJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999;30:787-93.
13. McHutchison JG, Poynard T, Pianko S, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 2000;119:1317-23.
14. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002;36:S21-9.
15. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50.
16. Costa MA, Schiff ER. Hepatitis C. Curr Treat Options Gastroenterol 1999;2:481-90.
17. Herrine SK. Approach to the patient with chronic hepatitis C virus infection. Ann Intern Med 2002;136:747-57.
18. Lindsay KL, Davis GL, Schiff ER, et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial. Hepatitis Interventional Therapy Group. Hepatology 1996;24:1034-40.
19. Kinzie JL, Naylor PH, Nathani MG, et al. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepat 2001;8:264-9.
20. De Maria N, Colantoni A, Idilman R, et al. Impaired response to high-dose interferon treatment in African-Americans with chronic hepatitis C. Hepatogastroenterology 2002;49:788-92.
21. Keating GM, Curran MP. Peginterferon-alpha-2a (40kD) plus ribavirin: A review of its use in the management of chronic hepatitis C. Drugs 2003;63:701-30.
22. Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjugate Chem 2001;12:195-202.
23. Glue P, Fang JWS, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000;68:556-67.
24. Wang Y-S, Youngster S, Bausch J, et al. Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry 2000;39:10634-40.
25. Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001;33:433-8.
26. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
27. Heathcote EJ, Shiftman ML, Cooksley WGE, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80.
28. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
29. Fried MW, Shiftman ML, Reddy ICR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
30. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-65.
31. Jeffers LJ, Cassidy W, Howell CD, et al. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004;39:1072-8.
32. Bedossa P, Darbere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-57.
33. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. Atlantic Coast Hepatitis Treatment Group. N Engl J Med 2004;350:2265-71.
34. Hoffman-Terry M, Khalili M, Bernstein D, et al. Safety and efficacy of peginterferon alfa-2a (40KD) (PEGASYS) with or without ribavirin in the treatment of patients coinfected with HIV and HCV: Preliminary results from a randomized, multicenter trial. Poster presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy's 42nd Annual Meeting; September 27-30, 2002; San Diego, CA.
35. Lam NP, Neumann AU, Gretch DR, et al. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997;26:226-31.
36. Layden-Almer JE, Ribeiro RM, Wiley T, et al. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003;37:1343-50.
37. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-9.
38. Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000;133:592-9.
39. Mason AL, Lau JYN, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999;29:328-33.
40. Khalili M, Lim JW, Bass N, et al. New onset diabetes mellitus after liver transplantation: The critical role of hepatitis C infection. Liver Transpl 2004;10:349-55.
41. Delgado-Borrego A, Casson D, Schoenfeld D, et al. Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation 2004;77:703-10.
42. Kimball P, Elswick RK, Shiffman M. Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-alpha therapy. J Med Virol 2001;65:510-6.
43. Sugimoto K, Stadanlick J, Ikeda F, et al. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology 2003;37:590-9.
44. Thio CL, Thomas DL, Goedert JJ, et al. Racial differences in HLA class II association with hepatitis C virus outcomes. J Infect Dis 2001;184:16-21.
45. Thursz M. MHC and the viral hepatitides. Q J Med 2001;94:287-91.
46. Hohler T, Kruger A, Gerken G, et al. Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection. J Med Virol 1998;54:173-7.
47. Powell EE, Edwards-Smith CJ, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000;31:828-33.
48. Edwards-Smith CJ, Jonsson JR, Purdie DM, et al. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999;30:526-30.
49. Knapp S, Hennig BJW, Frodsham AJ, et al. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 2003;55:362-9.
50. Hellier S, Frodsham AJ, Hennig BJW, et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 2003;38:1468-76.
51. Kazemi-Shirazi L, Datz C, Maier-Dobersberger T, et al. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology 1999;116:127-34.
52. Smith BC, Grove J, Guzail MA, et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998;27:1695-9.
53. Hézode C, Cazeneuve C, Coué O, et al. Liver iron accumulation in patients with chronic active hepatitis C: Prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J Hepatol 1999;31:979-84.
54. Hennig BJW, Hellier S, Frodsham AJ, et al. Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection. Genes Immun 2002;3:359-67.
55. Wright M, Goldin R, Hellier S, et al. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 2003;52:1206-10.
56. Knapp S, Yee LJ, Frodsham AJ, et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: Roles of MxA, OAS-1 and PKR. Genes Immun 2003;4:411-9.
57. Virahep-C. Hepatology 2002;36:532-3.
58. National Institute of Diabetes and Digestive and Kidney Diseases. VIRAHEP-C. Available at: http://www.edc.gsph.pitt.edu/virahepc. Accessed September 28, 2004.